Getinge (OTCMKTS:GNGBY) Hits New 1-Year High – Time to Buy?

Getinge (OTCMKTS:GNGBY)’s share price hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $26.88 and last traded at $26.76, with a volume of 2,714 shares changing hands. The stock had previously closed at $26.21.

Analyst Upgrades and Downgrades

GNGBY has been the topic of several research analyst reports. Nordea Equity Research lowered Getinge from a “buy” rating to a “hold” rating in a research note on Monday, August 31st. UBS Group started coverage on Getinge in a report on Wednesday, September 2nd. They set a “hold” rating for the company. Pareto Securities downgraded Getinge from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 24th. Finally, Zacks Research lowered Getinge from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 17th. Four equities research analysts have rated the stock with a Hold rating. According to MarketBeat, the stock has a consensus rating of “Hold”.

Getinge Stock Performance

The business has a 50-day moving average of $25.17 and a 200 day moving average of $22.78. The stock has a market cap of $7.22 billion, a PE ratio of 19.36 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.74 and a current ratio of 1.31.

Getinge (OTCMKTS:GNGBY) last released its earnings results on Wednesday, October 21st. The company reported $0.32 earnings per share (EPS) for the quarter. Getinge had a net margin of 8.20% and a return on equity of 11.55%. The company had revenue of $875.58 million for the quarter. Equities research analysts predict that Getinge will post 1.38 EPS for the current fiscal year.

About Getinge

Getinge AB is a Sweden-based medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support patient care, surgical procedures, infection prevention and the development and production of pharmaceuticals and other medical products.

The company’s portfolio includes equipment for intensive care and cardiovascular procedures, operating-room systems, surgical instruments, sterilization and disinfection solutions, and products used in laboratories and biopharmaceutical manufacturing.